Richeldi L, Collard HR, Jones MG, et al. Idiopathic PF. Lancet. 2017;389(10082):1941–52.

Article  Google Scholar 

Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic PF: a systematic review. Eur Respir J. 2015;46(3):795–806.

Article  Google Scholar 

Wijsenbeek M. Progress in the treatment of PF. Lancet Respir Med. 2020;8(5):424–5.

Article  Google Scholar 

Bisserier M, Milara J, Abdeldjebbar Y, et al. AAV1.SERCA2a Gene Therapy Reverses PF by Blocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis. Mol Ther. 2020;28(2):394–410.

CAS  Article  Google Scholar 

Ruigrok MJR, Frijlink HW, Melgert BN, et al. Gene therapy strategies for idiopathic PF: recent advances, current challenges, and future directions. Mol Ther Methods Clin Dev. 2021;20:483–96.

CAS  Article  Google Scholar 

Wu B, Tang L, Kapoor M. Fibroblasts and their responses to chronic injury in PF. Semin Arthritis Rheum. 2021;51(1):310–7.

CAS  Article  Google Scholar 

Wilson MS, Wynn TA. PF: pathogenesis, etiology and regulation. Mucosal Immunol. 2009;2(2):103–21.

CAS  Article  Google Scholar 

Sgalla G, Iovene B, Calvello M, et al. Idiopathic PF: pathogenesis and management. Respir Res. 2018;19(1):32.

Article  Google Scholar 

Lee SJ, Choi D, Rhim H, et al. E3 ubiquitin ligase RNF2 interacts with the S6’ proteasomal ATPase subunit and increases the ATP hydrolysis activity of S6’. Biochem J. 2005;389(Pt 2):457–63.

CAS  Article  Google Scholar 

Rai K, Akdemir KC, Kwong LN, et al. Dual roles of RNF2 in melanoma progression. Cancer Discov. 2015;5(12):1314–27.

CAS  Article  Google Scholar 

Wei M, Jiao D, Han D, et al. Knockdown of RNF2 induces cell cycle arrest and apoptosis in prostate cancer cells through the upregulation of TXNIP. Oncotarget. 2017;8(3):5323–38.

Article  Google Scholar 

Yan Q, Chen BJ, Hu S, et al. Emerging role of RNF2 in cancer: from bench to bedside. J Cell Physiol. 2021;236(8):5453–65.

CAS  Article  Google Scholar 

Choi D, Lee SJ, Hong S, et al. Prohibitin interacts with RNF2 and regulates E2F1 function via dual pathways. Oncogene. 2008;27(12):1716–25.

CAS  Article  Google Scholar 

Yang J, Yu F, Guan J, et al. Knockdown of RNF2 enhances the radiosensitivity of squamous cell carcinoma in lung. Biochem Cell Biol. 2019;97(5):589–99.

CAS  Article  Google Scholar 

Carpagnano GE, Lacedonia D, Soccio P, et al. How strong is the association between IPF and lung cancer? An answer from airway’s DNA. Med Oncol. 2016;33(11):119.

CAS  Article  Google Scholar 

Tzouvelekis A, Gomatou G, Bouros E, et al. Common pathogenic mechanisms between idiopathic pf and lung cancer. Chest. 2019;156(2):383–91.

Article  Google Scholar 

Gui YS, Wang L, Tian X, et al. mTOR overactivation and compromised autophagy in the pathogenesis of PF. PLoS ONE. 2015;10(9): e0138625.

Article  Google Scholar 

Han Q, Lin L, Zhao B, et al. Inhibition of mTOR ameliorates bleomycin-induced PF by regulating epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2018;500(4):839–45.

CAS  Article  Google Scholar 

Wong K, Di Cristofano F, Ranieri M, et al. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer. Endocr Relat Cancer. 2019;26(4):425–36.

CAS  Article  Google Scholar 

Saito A, Horie M, Micke P, et al. The Role of TGF-β signaling in lung cancer associated with idiopathic PF. Int J Mol Sci. 2018;19(11):3611.

Article  Google Scholar 

Zhang Y, Jiao H, Wu Y, et al. P120-catenin regulates PF and TGF-β induced lung fibroblast differentiation. Life Sci. 2019;230:35–44.

CAS  Article  Google Scholar 

Theocharis AD, Skandalis SS, Gialeli C, et al. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4–27.

CAS  Article  Google Scholar 

Hansen NU, Genovese F, Leeming DJ, et al. The importance of extracellular matrix for cell function and in vivo likeness. Exp Mol Pathol. 2015;98(2):286–94.

CAS  Article  Google Scholar 

Upagupta C, Shimbori C, Alsilmi R, et al. Matrix abnormalities in PF. Eur Respir Rev. 2018;27(148): 180033.

Article  Google Scholar 

Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020;21(24):9739.

CAS  Article  Google Scholar 

Wu L, Luo Z, Zheng J, et al. IL-33 can promote the process of pf by inducing the imbalance between MMP-9 and TIMP-1. Inflammation. 2018;41(3):878–85.

CAS  Article  Google Scholar 

Huang C, Xiao X, Yang Y, et al. MicroRNA-101 attenuates PF by inhibiting fibroblast proliferation and activation. J Biol Chem. 2017;292(40):16420–39.

CAS  Article  Google Scholar 

Hanson KM, Hernady EB, Reed CK, et al. Apoptosis resistance in fibroblasts precedes progressive scarring in pf and is partially mediated by toll-like receptor 4 activation. Toxicol Sci. 2019;170(2):489–98.

CAS  Article  Google Scholar 

Lv X, Li K, Hu Z. Autophagy and PF. Adv Exp Med Biol. 2020;1207:569–79.

CAS  Article  Google Scholar 

Yu JS, Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 2016;143(17):3050–60.

CAS  Article  Google Scholar 

Szwed A, Kim E, Jacinto E. Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev. 2021;101(3):1371–426.

CAS  Article  Google Scholar 

Huang CK, Iwagami Y, Zou J, et al. Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation. Cancer Lett. 2018;429:1–10.

CAS  Article  Google Scholar 

Cho HS, Hayami S, Toyokawa G, et al. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia. 2012;14(6):476–86.

CAS  Article  Google Scholar